Takeda Reports Zasocitinib Achieves High Psoriasis Clearance

Takeda announced Phase 3 results for zasocitinib (TAK-279) at the 2026 AAD meeting showing about 69–71% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 and significant PASI 75/90/100 improvements versus placebo and apremilast. Safety was consistent with Phase 2b with no new signals, responses deepened through week 24 and remained durable to week 60; Takeda plans NDA submissions starting fiscal 2026.